At‑home HPV test cleared
Regulators cleared a comprehensive at‑home cervical cancer screening kit that lets patients collect a sample at home and mail it to a lab for HPV testing and physician notification. Industry coverage frames this as expanding access outside pelvic exams and shifting more of the screening pathway toward molecular HPV testing and remote specimen collection. (pharmacytimes.com)
A cervical cancer screening kit that lets patients collect a vaginal sample at home for human papillomavirus testing has won United States Food and Drug Administration clearance for broader at-home use. (pharmacytimes.com) Waters said on April 8 that the Food and Drug Administration cleared its Onclarity human papillomavirus Self-Collection Kit and approved the BD Onclarity human papillomavirus assay with extended genotyping for home-collected samples. The company said the kit will be available by prescription in the coming months. (prnewswire.com) Human papillomavirus is a common virus, and long-lasting infection with high-risk types causes virtually all cervical cancers. Screening looks for the virus before cell changes turn into cancer. (cancer.gov) The test does not diagnose cancer from a home swab by itself. It checks for 14 high-risk human papillomavirus types, and the BD assay reports six types individually, which can help guide follow-up after a positive result. (pharmacytimes.com) Federal screening policy has been moving toward human papillomavirus-first testing. The Health Resources and Services Administration said on January 5, 2026, that updated women’s preventive health guidelines now include self-collection and name high-risk human papillomavirus testing, whether patient- or clinician-collected, as the preferred option for average-risk women ages 30 to 65. (hrsa.gov) Older United States Preventive Services Task Force guidance already allowed several screening paths: Pap testing every three years for ages 21 to 29, and for ages 30 to 65 either Pap testing every three years, high-risk human papillomavirus testing every five years, or both together every five years. The task force says that recommendation is now being updated. (uspreventiveservicestaskforce.org) The access problem is large. The Centers for Disease Control and Prevention says the United States records about 13,000 new cervical cancer cases and about 4,000 deaths each year. (cdc.gov) Waters said about 60% of cervical cancer cases occur in people who are unscreened or under-screened, the group this kind of mail-in testing is meant to reach. Pharmacy Times also cited persistent disparities, including higher incidence and mortality in Black women and barriers tied to geography, language, culture, and cost. (prnewswire.com; pharmacytimes.com) This is not the first time regulators have backed home collection for cervical screening. Teal Health said in May 2025 that the Food and Drug Administration approved its Teal Wand, which paired at-home sample collection with telehealth and lab testing. (getteal.com) What changes now is the shape of the screening visit: instead of starting with a pelvic exam in a clinic, some patients can start with a prescription, a home collection kit, and a lab result. If the result is positive, follow-up care still moves back into the medical system. (pharmacytimes.com; hrsa.gov)
